ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 13 (2) 583-592    DOI: 10.1677/erc.1.01149
Copyright © 2006 by the Society for Endocrinology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Link to related commentary
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schernhammer, E. S
Right arrow Articles by Hankinson, S. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schernhammer, E. S
Right arrow Articles by Hankinson, S. E

Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II

Eva S Schernhammer1,2, Jeff M Holly3, David J Hunter1,4, Michael N Pollak5 and Susan E Hankinson1,5

1 Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, Massachusetts 02115, USA
2 LBI-ACR VIEnna & ACR-ITR VIEnna, Vienna, Austria
3 Department of Surgery, Bristol Royal Infirmary, Bristol, United Kingdom
4 Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
5 Departments of Medicine and Oncology, McGill University, Montréal, Québec, Canada H3T 1E2

(Requests for offprints should be addressed to E S Schernhammer; Email: eva.schernhammer{at}channing.harvard.edu)

Earlier data suggest that the relationship between circulating insulin-like growth factor I (IGF-I) levels and breast cancer risk differs according to menopausal status. We evaluated the association between IGF levels as well as the primary regulator of IGF-I production, growth hormone (GH), and breast cancer risk in the Nurses’ Health Study II (NHS II) cohort, a large cohort of primarily premenopausal women. We conducted a case-control study nested within the prospective NHS II cohort. Plasma concentrations of IGF-I, IGF binding protein (IGFBP)-3, IGFBP-1, and GH were measured in blood samples collected between 1996 and 1999. Totally 317 women were identified who had a diagnosis of invasive or in situ breast cancer between the date of blood collection and June 1 2003; 75% of these women were premenopausal at blood collection. To each of the 317 women, two controls were age-matched for a total of 634 controls. We used conditional logistic regression models to estimate the relative risk of breast cancer. Overall, plasma IGF-I, IGFBP-1, IGFBP-3, and GH levels were not associated with breast cancer risk (relative risks, top vs bottom quartile; IGF-I, 0.98, 95% confidence interval (CI), 0.69–1.39; IGFBP-1, 0.95, 95% CI, 0.63–1.41; IGFBP-3, 1.10, 95% CI, 0.78–1.54; GH, 1.09, 95% CI, 0.82–1.46). These risks were similar for premenopausal women of age 45 years or less. Further adjustment for additional breast cancer risk factors did not change these estimates. In conclusion, circulating IGF-I, IGFBP-1, IGFBP-3, and GH levels appear to have no important association with breast cancer risk in a large cohort of premenopausal women.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
N. B. Peterson, Y. Huang, P. A. Newcomb, L. Titus-Ernstoff, A. Trentham-Dietz, G. Anic, and K. M. Egan
Childbearing Recency and Modifiers of Premenopausal Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3284 - 3287.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
J. H. Page, J. Ma, M. Pollak, J. E. Manson, and S. E. Hankinson
Plasma Insulinlike Growth Factor 1 and Binding-Protein 3 and Risk of Myocardial Infarction in Women: A Prospective Study
Clin. Chem., October 1, 2008; 54(10): 1682 - 1688.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. K. de Ostrovich, I. Lambertz, J. K. L. Colby, J. Tian, J. E. Rundhaug, D. Johnston, C. J. Conti, J. DiGiovanni, and R. Fuchs-Young
Paracrine Overexpression of Insulin-Like Growth Factor-1 Enhances Mammary Tumorigenesis in Vivo
Am. J. Pathol., September 1, 2008; 173(3): 824 - 834.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. J. Vatten, J. M. Holly, D. Gunnell, and S. Tretli
Nested Case-Control Study of the Association of Circulating Levels of Serum Insulin-like Growth Factor I and Insulin-like Growth Factor Binding Protein 3 with Breast Cancer in Young Women in Norway
Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2097 - 2100.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
B. J. Fuhrman, B. E. Teter, M. Barba, C. Byrne, A. Cavalleri, B. J. Grant, P. J. Horvath, D. Morelli, E. Venturelli, and P. C. Muti
Equol Status Modifies the Association of Soy Intake and Mammographic Density in a Sample of Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 33 - 42.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
E. S Schernhammer, S. S Tworoger, A H. Eliassen, S. A Missmer, J. M Holly, M. N Pollak, and S. E Hankinson
Body shape throughout life and correlations with IGFs and GH
Endocr. Relat. Cancer, September 1, 2007; 14(3): 721 - 732.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
F. Xue and K. B Michels
Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence
Am. J. Clinical Nutrition, September 1, 2007; 86(3): 823S - 835S.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. Baglietto, D. R. English, J. L. Hopper, H. A. Morris, W. D. Tilley, and G. G. Giles
Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 763 - 768.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Verheus, P. H.M. Peeters, R. Kaaks, P. A.H. van Noord, D. E. Grobbee, and C. H. van Gils
Premenopausal Insulin-Like Growth Factor-I Serum Levels and Changes in Breast Density over Menopause
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 451 - 457.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
K. Pazaitou-Panayiotou, T. Kelesidis, I. Kelesidis, A. Kaprara, J. Blakeman, I. Vainas, A. Mpousoulegas, C. J Williams, and C. Mantzoros
Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer
Eur. J. Endocrinol., February 1, 2007; 156(2): 187 - 194.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. H. Eliassen, S. S. Tworoger, C. S. Mantzoros, M. N. Pollak, and S. E. Hankinson
Circulating Insulin and C-Peptide Levels and Risk of Breast Cancer among Predominately Premenopausal Women
Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 161 - 164.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
K. L. Campbell and A. McTiernan
Exercise and Biomarkers for Cancer Prevention Studies
J. Nutr., January 1, 2007; 137(1): 161S - 169S.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Lukanova, P. Toniolo, A. Zeleniuch-Jacquotte, K. Grankvist, M. Wulff, A. A. Arslan, Y. Afanasyeva, R. Johansson, P. Lenner, G. Hallmans, et al.
Insulin-like Growth Factor I in Pregnancy and Maternal Risk of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2489 - 2493.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. G Renehan, M. Harvie, and A. Howell
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 273 - 278.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Endocrinology.